Pulling SEC filings + quote and writing the call…

Immunovant, Inc.
Next earnings Aug 10, 2026 · consensus $-0.61 EPS
Last earnings +35.3% on 2026-05-20
Clinical-stage FcRn play with no revenue and a $506M loss; a recent Phase 3 failure narrows it to a single binary bet on IMVT-1402.
Immunovant is a pre-revenue, clinical-stage immunology company whose value rests entirely on IMVT-1402, a potentially best-in-class anti-FcRn antibody for IgG-mediated autoimmune diseases. The financials are pure cash-burn: no product revenue, a -$506M net loss (EPS -$2.77), -$407M operating cash burn, and a -$1.75B accumulated deficit. The company itself states current funds 'will not be sufficient' to complete development and launch across all indications it is evaluating, and expects to keep incurring losses for the foreseeable future.
Sources: SEC EDGAR (CIK 0001764013, latest 10-K filed 2026-05-20) · EODHD · analysis by claude-code · as of 6/21/2026, 8:53:47 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.
The risks, catalysts, 12-month price target and the cited SEC figures behind this rating — with Pro.
Unlock with Pro€15/mo · cancel anytime
| Line item | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | — | — | — | — | — |
| Net income | -$157M | -$211M | -$259M | -$414M | -$506M |
| Diluted EPS | -$1.43 | -$1.71 | -$1.88 | -$2.73 | -$2.77 |
| Net margin | — | — | — | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
1078 tracked peers · median
Dates from 8-K (Item 2.02); beat/miss = reported EPS vs consensus (Finnhub, recent quarters); move = prior close → close on/after.
Recent news tone vs the market's typical (which skews positive). A soft signal, not a recommendation.
Last 90 days: 0 open-market buys · 11 sales
| 2026-06-18 | Van Tuyl Christopher Chief Legal Officer | Sell | 2.63K @ $35.39 | $93.2K |
| 2026-06-15 | Pande Atul Director | Exercise | 1.50K @ $8.43 | $12.6K |
| 2026-06-15 | Pande Atul Director | Sell | 1.50K @ $34.02 | $51.0K |
| 2026-05-28 | Fromkin Andrew J. Director | Exercise | 31.7K @ $4.99 | $158K |
| 2026-05-28 | Fromkin Andrew J. Director | Exercise | 71.5K @ $7.94 | $568K |
| 2026-05-28 | Fromkin Andrew J. Director | Exercise | 77.2K @ $8.43 | $651K |
| 2026-05-28 | Fromkin Andrew J. Director | Exercise | 16.3K @ $14.70 | $239K |
| 2026-05-28 | Fromkin Andrew J. Director | Sell | 11.5K @ $32.64 | $375K |
| 2026-05-28 | Fromkin Andrew J. Director | Sell | 210K @ $33.56 | $7.06M |
| 2026-05-20 | Gloria Melanie Chief Operating Officer | Sell | 249.00 @ $30.41 | $7.57K |
| 2026-05-20 | Gloria Melanie Chief Operating Officer | Sell | 1.17K @ $32.15 | $37.6K |
| 2026-05-20 | Gloria Melanie Chief Operating Officer | Sell | 1.70K @ $32.95 | $55.9K |